Jefferies Cuts Price Target on Immunomedics (IMMU) as Clivatuzumab Program is Discontinued
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
After-Hours Stock Movers 03/14: (CPXX) (SZYM) (ESI) Higher; (IMMU) (MNKD) (NVIV) Lower (more...)
March 14, 2016 6:09 PM EDTCelator Pharmaceuticals, Inc. (Nasdaq: CPXX) 373% HIGHER; announced positive results from the Phase 3 trial of VYXEOS (cytarabine: daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML) compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3. The trial met its primary endpoint demonstrating a statistically significant improvement in overall survival.
Solazyme, Inc. (Nasdaq: SZYM) 29.5% HIGHER; has signed a definitive multi-year global supply agreement with Unilever.... More
Immunomedics (IMMU) to Terminate Phase 3 PANCRIT-1 w/ 90Y in Metastatic Pancreatic Cancer
March 14, 2016 4:31 PM EDTImmunomedics, Inc., (Nasdaq: IMMU) announced that the Company is terminating the Phase 3 PANCRIT-1 trial with yttrium-90-labeled (90Y) clivatuzumab tetraxetan in patients... More
